Clare Tempany, MB BAO BCh, presented “PI-RADS Standardization and Risk Assessment – Recent Advances and Future Plans” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 21, 2023.

This content is available free to the GRU Community. Login or create an account to view it.


Create an Account

How to cite: Tempany, Clare. PI-RADS Standardization and Risk Assessment – Recent Advances and Future Plans.” September 21, 2023. Accessed Jul 2024.

PI-RADS Standardization and Risk Assessment – Recent Advances and Future Plans – Summary

Clare Tempany, MB BCh BAO, gives an overview of the role that Prostate Imaging Reporting And Data System (PI-RADS) standardization plays in the treatment and detection of prostate cancer. She begins by giving a history of the RADS program, which is overseen by the American College of Radiation, and the objectives of RAD programs overall. 

Dr. Tempany then goes into detail about the PI-RADS program and its specific objectives. She discusses the need to change and update existing RADS, highlighting the lack of consensus on two significant studies that would prompt such changes. 

Dr. Tempany concludes by reviewing technical specifications, clarifications in interpretation criteria, and the role of Bi-Parametiric MRI in PI-RADS. She finishes her talk by going over possible research opportunities and other exciting future plans.

The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.


Dr. Tempany is the Ferenc A. Jolesz Professor of Radiology at Harvard Medical School in Boston, Massachusetts. She also serves as Vice Chair of Radiology Research and Medical Director of the Advanced Multi-modal Image Guided Operating (AMIGO) Suite, a suite of translational clinical research rooms at Brigham & Women’s Hospital in Boston. Dr. Tempany is a native of Dublin, Ireland, and a graduate of the Royal College of Surgeons in Ireland. She completed her internship and a senior house officer program in internal medicine in Dublin prior to moving to Chicago for residency training in Diagnostic Radiology at Loyola University of Chicago. She went on to a fellowship and her first faculty appointment in MRI at Johns Hopkins Medical Institutions in Baltimore, Maryland. Three years later, she moved to Brigham & Women’s Hospital to join the Abdominal Imaging Division.

Dr. Tempany established the Body MRI Program at Brigham & Women’s Hospital with a pioneering focus on prostate and gynecological imaging. Then, through a unique partnership with Anthony D’Amico, MD, she helped establish the first ever MR-guided prostate cancer brachytherapy program in 1997. She followed this by partnering with Noby Hata, PhD, to establish the first MR-guided transperineal in-bore prostate cancer biopsy program. Now, 20 years later, both MR-guided prostate cancer biopsy and MR-guided radiation therapy are rapidly becoming the standard of care to aid in prostate cancer diagnosis and treatment.

Today, Dr. Tempany leads trials in mpMRI, is Co-Chair of the PI-RADS international committee, is the PI of a InSightec-sponsored focal therapy trial with MR-guided FUS, and is study chair of the new ECOG-ACRIN trial in prostate MRI. She has had continuous NIH funding for over 20 years and is currently the PI of the NIH funded-P41, and a T32 training grant in image-guided therapy.